Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...

Corcept Therapeutics (NASDAQ:CORT) is gearing up to announce its quarterly earnings on Wednesday, 2024-10-30. Here's a quick overview of what investors should know before the release. Analysts are ...

Corcept's Phase 3 GRADIENT trial for relacorilant has missed its primary endpoint – the improvement in SBP for Cushing's ...

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a ...

The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 27 cents per share. The drug developer posted revenue of $182.5 million in the period, which also beat ...

List today: American Assets Trust, Inc. AAT: This self-administered real estate investment trust has seen the Zacks Consensus ...